Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
NY Center for Women's Health Research
mi
from
New York, NY
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
NY Center for Women's Health Research
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Clinical Trials of America, Inc
mi
from
Winston-Salem, NC
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Clinical Trials of America, Inc
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Hawthorne Medical Research, Inc.
mi
from
Winston-Salem, NC
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Hawthorne Medical Research, Inc.
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Columbus Center for Women's Health Research
mi
from
Columbus, OH
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Columbus Center for Women's Health Research
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Complete Healthcare for Women
mi
from
Columbus, OH
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Complete Healthcare for Women
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
HWC Women's Research Center
mi
from
Englewood, OH
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
HWC Women's Research Center
mi
from
Englewood, OH
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
University Hospitals of Cleveland Landerbrook Health Center
mi
from
Mayfield Heights, OH
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
University Hospitals of Cleveland Landerbrook Health Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Sooner Clinical Research
mi
from
Oklahoma City, OK
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Sooner Clinical Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Philadelphia Clinical Research
mi
from
Philadelphia, PA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Philadelphia Clinical Research
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Clinical Trials Research Services, LLC
mi
from
Pittsburgh, PA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Clinical Trials Research Services, LLC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Susan L Floyd, MD, PC
mi
from
Wexford, PA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Susan L Floyd, MD, PC
mi
from
Wexford, PA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Partners in Clinical Research, LLC
mi
from
Cumberland, RI
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Partners in Clinical Research, LLC
mi
from
Cumberland, RI
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Coastal Carolina Research Center
mi
from
Mt. Pleasant, SC
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Coastal Carolina Research Center
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Chattanooga Medical Research, LLC
mi
from
Chattanooga, TN
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Chattanooga Medical Research, LLC
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Access Clinical Trials
mi
from
Nashville, TN
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Access Clinical Trials
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Tekton Research
mi
from
Austin, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Tekton Research
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
DiscoveResearch, Inc.
mi
from
Bryan, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
DiscoveResearch, Inc.
mi
from
Bryan, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Advances In Health, Inc.
mi
from
Houston, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Advances In Health, Inc.
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
The Woman's Hospital of Texas Clinical Research Center
mi
from
Houston, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
The Woman's Hospital of Texas Clinical Research Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Research Across America
mi
from
Katy, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Research Across America
mi
from
Katy, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Radiant Research, Inc
mi
from
San Antonio, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Radiant Research, Inc
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Virginia Women's Center
mi
from
Richmond, VA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Virginia Women's Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
National Clinical Research, Inc.
mi
from
Richmond, VA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
National Clinical Research, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Tidewater Clinical Research Inc
mi
from
Virginia Beach, VA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Tidewater Clinical Research Inc
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Women's Clinical Research Center
mi
from
Seattle, WA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Women's Clinical Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
North Spokane Women's Clinic Research
mi
from
Spokane, WA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
North Spokane Women's Clinic Research
mi
from
Spokane, WA
Click here to add this to my saved trials
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
Evaluation of Pharmacokinetics of Paroxetine Following Single and Repeat Oral Administration of Mesafem (7.5 mg Paroxetine Mesylate) Capsules in Healthy Postmenopausal Women
Status: Enrolling
Updated:  10/14/2015
SNBL Clinical Pharmacology Center
mi
from
Baltimore, MD
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
Evaluation of Pharmacokinetics of Paroxetine Following Single and Repeat Oral Administration of Mesafem (7.5 mg Paroxetine Mesylate) Capsules in Healthy Postmenopausal Women
Status: Enrolling
Updated: 10/14/2015
SNBL Clinical Pharmacology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  10/16/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 10/16/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Gene Expression In Pregnancies Complicated by Preeclampsia
Expression of Vascular Endothelial Growth Factor and Its Effectors in Preeclampsia
Status: Enrolling
Updated:  10/19/2015
Univ of Rochester Medical Center
mi
from
Rochester, NY
Gene Expression In Pregnancies Complicated by Preeclampsia
Expression of Vascular Endothelial Growth Factor and Its Effectors in Preeclampsia
Status: Enrolling
Updated: 10/19/2015
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Cue-based Tactile Stimulation and Infant Stress Reactivity
Effect of Cue-based Tactile Stimulation on Premature, Low Birth Weight Infants: Stress Reactivity.Immune Functioning, and Parenting
Status: Enrolling
Updated:  10/19/2015
Penn State Hershey Children's Hospital
mi
from
Hershey, PA
Cue-based Tactile Stimulation and Infant Stress Reactivity
Effect of Cue-based Tactile Stimulation on Premature, Low Birth Weight Infants: Stress Reactivity.Immune Functioning, and Parenting
Status: Enrolling
Updated: 10/19/2015
Penn State Hershey Children's Hospital
mi
from
Hershey, PA
Click here to add this to my saved trials
ShuntCheck Versus Radionuclide in Evaluating Shunt Function in Symptomatic NPH Patients
A Double- Blinded Comparison of the Accuracy of ShuntCheck, a Non-Invasive Device, to Radionuclide Shunt Patency Test in Evaluating Shunt Function in Patients With Adult Hydrocephalus With Possible Shunt Obstruction
Status: Enrolling
Updated:  10/19/2015
Sinai Hospital of Baltimore, LifeBridge Health
mi
from
Baltimore, MD
ShuntCheck Versus Radionuclide in Evaluating Shunt Function in Symptomatic NPH Patients
A Double- Blinded Comparison of the Accuracy of ShuntCheck, a Non-Invasive Device, to Radionuclide Shunt Patency Test in Evaluating Shunt Function in Patients With Adult Hydrocephalus With Possible Shunt Obstruction
Status: Enrolling
Updated: 10/19/2015
Sinai Hospital of Baltimore, LifeBridge Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
US Eeva™ Pregnancy Investigational Clinical Study (US EPIC)
US Eeva™ Pregnancy Investigational Clinical Study (US EPIC)
Status: Enrolling
Updated:  10/19/2015
Fertility Physicians of Northern California
mi
from
San Jose, CA
US Eeva™ Pregnancy Investigational Clinical Study (US EPIC)
US Eeva™ Pregnancy Investigational Clinical Study (US EPIC)
Status: Enrolling
Updated: 10/19/2015
Fertility Physicians of Northern California
mi
from
San Jose, CA
Click here to add this to my saved trials
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase I Trial of Lithium and Tretinoin for Treatment of Non-Promyelocytic Acute Myeloid Leukemia in Patients Intolerant or Relapsed/Refractory to Standard Chemotherapy.
Status: Enrolling
Updated:  10/19/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase I Trial of Lithium and Tretinoin for Treatment of Non-Promyelocytic Acute Myeloid Leukemia in Patients Intolerant or Relapsed/Refractory to Standard Chemotherapy.
Status: Enrolling
Updated: 10/19/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effects of Preoperative Dexamethasone Study on QOL After Vaginal Reconstructive Surgery for POP
Effects of Preoperative Dexamethasone on Postoperative Quality of Recovery Following Vaginal Reconstructive Surgery: A Randomized Controlled Trial
Status: Enrolling
Updated:  10/19/2015
Triheath
mi
from
Cincinnati, OH
Effects of Preoperative Dexamethasone Study on QOL After Vaginal Reconstructive Surgery for POP
Effects of Preoperative Dexamethasone on Postoperative Quality of Recovery Following Vaginal Reconstructive Surgery: A Randomized Controlled Trial
Status: Enrolling
Updated: 10/19/2015
Triheath
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
University of Alabama
mi
from
Birmingham, AL
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Dept of OB/GYN, University of Miami
mi
from
Miami, FL
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Dept of OB/GYN, University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Northwestern University
mi
from
Chicago, IL
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Dept of OB/GYN, Hutzel Hospital
mi
from
Detroit, MI
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Dept of OB/GYN, Hutzel Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
St. Luke's Roosevelt Hospital
mi
from
New York, NY
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
St. Luke's Roosevelt Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Forsyth Memorial Hospital, Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Forsyth Memorial Hospital, Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
The University Hospital, University of Cincinnati
mi
from
Cincinnati, OH
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
The University Hospital, University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Case Western University
mi
from
Cleveland, OH
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Case Western University
mi
from
Cleveland, OH
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Dept of OB/GYN, Ohio State University
mi
from
Columbus, OH
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Dept of OB/GYN, Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
MCP Hahnemann University
mi
from
Philadelphia, PA
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
MCP Hahnemann University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Dept of OB/GYN Magee Womens Hospital
mi
from
Pittsburgh, PA
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Dept of OB/GYN Magee Womens Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials